NEW YORK CITY (dpa-AFX) - GSK plc (GSK, GSK.L) and CureVac N.V. (CVAC)
announced that they have restructured their current collaboration through a new
licensing agreement. This allows both companies to prioritize investment and
concentrate on their respective mRNA development activities.

As per the terms of the new agreement, GSK will assume full control of
developing and manufacturing mRNA candidate vaccines for influenza and COVID-19,
including combinations. GSK will have worldwide rights to commercialise the
candidate vaccines.

GSK continues to develop and optimise its mRNA capabilities through investments
and partnerships, including in AI/ML-based sequence optimisation, nanoparticle
design and manufacturing.

CureVac will receive an upfront payment of 400 million euros and up to an
additional 1.05 billion euros in development, regulatory and sales milestones
and tiered royalties in the high single to low teens range. The new agreement
replaces all previous financial considerations from the prior collaboration
agreement between GSK and CureVac.

CureVac further retains exclusive rights to the additional undisclosed and
preclinically validated infectious disease targets from the prior collaboration
together with the freedom to independently develop and partner mRNA vaccines in
any other infectious disease or other indication.

CureVac said its ongoing patent litigation against Pfizer/BioNTech is unaffected
by the new agreement.

Since 2020, GSK and CureVac have collaborated on the development of mRNA
vaccines for infectious diseases. Together, they have advanced vaccine
candidates for seasonal influenza and COVID-19 to phase II, with an avian
influenza candidate in phase I clinical development. The candidates utilize
CureVac's proprietary second-generation mRNA backbone.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX